All In Biotech

Free tool

FAERS Monitor: Zolymbus

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217307 or its brand name (Zolymbus, Bimatoprost). Reports on generic versions are filed under their own applications.

Reports

2,298

Serious

1,551

67% of reports

Hospitalization

667

Death reported

127

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective250
  • ocular hyperaemia88
  • eye irritation81
  • nausea79
  • dyspnoea78
  • diarrhoea71
  • fatigue71
  • eye pain66
  • headache63
  • madarosis61
  • dizziness56
  • rash56
  • off label use55
  • fall53
  • intraocular pressure increased53

Reports by year received

View as table
YearReports
200410
20054
20068
200712
200821
200922
201023
201136
201221
201351
201465
201582
2016119
2017207
2018180
2019198
2020189
2021184
2022151
2023219
2024178
2025167
2026151

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,861 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
madarosisSignal6148.337.72,768
intraocular pressure increasedSignal5338.129.21,872
ocular hyperaemiaSignal8817.013.81,310
eye irritationSignal8112.910.4878
eye painSignal6610.78.4573
drug ineffective2501.71.582
fall531.51.17
dyspnoea781.31.04
rash561.20.91
dizziness561.00.80
diarrhoea711.00.80
headache630.90.70
nausea790.90.71
fatigue710.80.72
off label use550.60.418

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.